Translate this page into:
Letter to the Editor
doi:
10.4103/sajc.sajc_166_19
A rare case of hyperprogression of nonsmall cell lung cancer in a patient on atezolizumab therapy
1
Department of Medical Oncology, St Michael's Medical Center, Newark, NJ, an Affiliate of New York Medical College, Westchester, NY
*Corresponding author: Dr. Hamid Shaaban. hamidshaaban@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920-8.
- Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605-11.
- Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, et al. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol 2018;36:1703-9.
- Salhan D, Verma P, Basunia M. Unusual presentation of clostridium difficile: Hepatic portal venous gas and gastric emphysema. Chest 2016;150:264A.
- Yoshida T, Furuta H, Hida T. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. Med Oncol 2017;34:34.
- Chubachi S, Yasuda H, Irie H, Fukunaga K, Naoki K, Soejima K, et al. A case of non-small cell lung cancer with possible “disease flare” on nivolumab treatment. Case reports in oncological medicine. 2016;2016.
- Ferrara R, Caramella C, Texier M, Audigier Valette C, Tessonnier L, Mezquita L, et al. 1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO). Ann Oncol 2017;28(suppl_5).
- Singavi AK, Menon S, Kilari D, Alqwasmi A, Ritch PS, Thomas JP, et al, George B. 1140PDPredictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)–analysis of somatic alterations (SAs). Ann Oncol 2017;28(suppl_5).
- Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017;23:4242-50.